|
1
|
Boussiotis VA: Molecular and biochemical
aspects of the PD-1 checkpoint pathway. N Engl J Med.
375:1767–1778. 2016.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Coles SJ, Gilmour MN, Reid R, Knapper S,
Burnett AK, Man S, Tonks A and Darley RL: The immunosuppressive
ligands PD-L1 and CD200 are linked in AML T-cell immunosuppression:
Identification of a new immunotherapeutic synapse. Leukemia.
29:1952–1954. 2015.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Lim SH, Sun JM, Lee SH, Ahn JS, Park K and
Ahn MJ: Pembrolizumab for the treatment of non-small cell lung
cancer. Expert Opin Biol Ther. 16:397–406. 2016.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Robert C, Ribas A, Schachter J, Arance A,
Grob JJ, Mortier L, Daud A, Carlino MS, McNeil CM, Lotem M, et al:
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006):
Post-hoc 5-year results from an open-label, multicentre,
randomised, controlled, phase 3 study. Lancet Oncol. 20:1239–1251.
2019.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Rini BI, Plimack ER, Stus V, Gafanov R,
Hawkins R, Nosov D, Pouliot F, Alekseev B, Soulières D, Melichar B,
et al: Pembrolizumab plus axitinib versus sunitinib for advanced
renal-cell carcinoma. N Engl J Med. 380:1116–1127. 2019.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Fradet Y, Bellmunt J, Vaughn DJ, Lee JL,
Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi
A, et al: Randomized phase III KEYNOTE-045 trial of pembrolizumab
versus paclitaxel, docetaxel, or vinflunine in recurrent advanced
urothelial cancer: Results of >2 years of follow-up. Ann Oncol.
30:970–976. 2019.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Gao HX, Huang SG, Du JF, Zhang XC, Jiang
N, Kang WX, Mao J and Zhao Q: Comparison of prognostic indices in
NSCLC patients with brain metastases after radiosurgery. Int J Biol
Sci. 14:2065–2072. 2018.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Cuzzubbo S, Javeri F, Tissier M, Roumi A,
Barlog C, Doridam J, Lebbe C, Belin C, Ursu R and Carpentier AF:
Neurological adverse events associated with immune checkpoint
inhibitors: Review of the literature. Eur J Cancer. 73:1–8.
2017.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Wang DY, Salem JE, Cohen JV, Chandra S,
Menzer C, Ye F, Zhao S, Das S, Beckermann KE, Ha L, et al: Fatal
toxic effects associated with immune checkpoint inhibitors: A
systematic review and meta-analysis. JAMA Oncol. 4:1721–1728.
2018.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Feng S, Coward J, McCaffrey E, Coucher J,
Kalokerinos P and O'Byrne K: Pembrolizumab-induced encephalopathy:
A review of neurological toxicities with immune checkpoint
inhibitors. J Thorac Oncol. 12:1626–1635. 2017.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Thompson JA, Schneider BJ, Brahmer J,
Andrews S, Armand P, Bhatia S, Budde LE, Costa L, Davies M,
Dunnington D, et al: Management of immunotherapy-related
toxicities, version 1.2019. J Natl Compr Canc Netw. 17:255–289.
2019.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Garcia CA, El-Ali A, Rath TJ, Contis LC,
Gorantla V, Drappatz J and Davar D: Neurologic immune-related
adverse events associated with adjuvant ipilimumab: Report of two
cases. J Immunother Cancer. 6(83)2018.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Johnson DB, Balko JM, Compton ML, Chalkias
S, Gorham J, Xu Y, Hicks M, Puzanov I, Alexander MR, Bloomer TL, et
al: Fulminant myocarditis with combination immune checkpoint
blockade. N Engl J Med. 375:1749–1755. 2016.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Tarhini AA, Zahoor H, Lin Y, Malhotra U,
Sander C, Butterfield LH and Kirkwood JM: Baseline circulating
IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of
relapse in ipilimumab neoadjuvant therapy of melanoma. J Immunother
Cancer. 3(39)2015.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Feng T, Qin H, Wang L, Benveniste EN,
Elson CO and Cong Y: Th17 cells induce colitis and promote Th1 cell
responses through IL-17 induction of innate IL-12 and IL-23
production. J Immunol. 186:6313–6318. 2011.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Osorio JC, Ni A, Chaft JE, Pollina R,
Kasler MK, Stephens D, Rodriguez C, Cambridge L, Rizvi H, Wolchok
JD, et al: Antibody-mediated thyroid dysfunction during T-cell
checkpoint blockade in patients with non-small-cell lung cancer.
Ann Oncol. 28:583–589. 2017.PubMed/NCBI View Article : Google Scholar
|
